OC vs RTX

The deterministic health profile is severely compromised, highlighted by a weak Piotroski F-Score of 2/9 and a bearish technical trend of 0/100. While analysts maintain a 'Buy' rating with a target of $138.19, the hard data reveals a sharp fundamental reversal characterized by negative profit margins (-5.17%) and crashing growth metrics. Revenue is declining rapidly (-16.8% YoY, -24.58% Q/Q) and EPS has plummeted by 65.8% YoY. The disconnect between analyst optimism and the deteriorating financial health suggests a significant risk of further price correction.

RTX exhibits stable financial health with a Piotroski F-Score of 5/9, yet it is trading at a severe premium compared to its Graham Number ($73.73) and Intrinsic Value ($96.67). While the company boasts an exceptional track record of earnings beats over 25 quarters and solid revenue growth, the valuation is stretched with a PEG ratio of 2.75. This fundamental overvaluation is compounded by bearish insider sentiment and a weak technical trend, suggesting that while the business is strong, the stock price is currently decoupled from its deterministic value.